Bristol-Myers’ tight-lipped pass on accelerated lung cancer drug approval leaves field wide open for Merck
January 20, 2017 at 11:11 AM EST
The announcement sent Bristol shares plummeting nearly 10%, with Merck stock gaining nearly 4%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.